Evercore ISI Maintains NovoCure Outperform, Cuts Price Target to $20
Evercore ISI maintained its Outperform rating on NovoCure and lowered its price target to $20 from $23.
Evercore ISI maintained its Outperform rating on NovoCure and lowered its price target to $20 from $23.